The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
Abstract
The National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted a randomized clinical trial to determine whether tamoxifen (TAM) plus chemotherapy is more effective than TAM alone in improving disease-free survival (DFS), distant disease-free survival (DDFS), and survival (S) of positive-node, TAM-responsive patients aged greater than or equal to 50 years. Women were randomized among three treatment groups: (1) TAM alone, (2) Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), cyclophosphamide, and TAM (ACT), or (3) melphalan (L-PAM), fluorouracil (5-FU), and TAM (PFT). The PFT arm was later modified so that new patients also received Adriamycin (PAFT). Findings from 1,124 eligible patients through 3 years of follow-up indicated a significantly better DFS for ACT-treated patients than for those receiving TAM alone (84% v 67%; P = .0004). An advantage in DDFS and S was also observed after ACT therapy (83% v 73% [P = .04 in the former] and 93% v 85% [P = .04 in the latter]). Both the DFS and DDFS of PAFT-treated patients were better than in those treated by TAM alone (83% v 66%, P = .0002 and 85% v 73%, P = .003). PFT patients also fared better in DFS and DDFS than TAM patients (81% v 72%, P = .07 and 85% v 74%, P = .02). Odds ratios consistently favored the three TAM-plus-chemotherapy groups. No significant S advantage is as yet evident in favor of the PAFT or PFT groups. Of importance is the failure of these studies to demonstrate an unfavorable interaction between the drug regimens used and the TAM, which was administered simultaneously. The findings related to the use of PAFT and PFT are of more biologic than clinical significance since L-PAM is rarely used in the treatment of breast cancer. The major conclusion from this study is the observance of a better outcome in positive-node breast cancer patients aged greater than or equal to 50 years from the use of postoperative prolonged TAM and short-course AC therapy (completed in 63 days) than from prolonged TAM therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Maximum utilization of the life table method in analyzing survival
Cutler, S. J., & Ederer, F. (1958) · Journal of Chronic Diseases · doi:10.1016/0021-9681(58)90126-7 · Cited by 2,870
Fisher, B., Bauer, M., Margolese, R., Poisson, R., Pilch, Y., Redmond, C., Fisher, E., Wolmark, N., Deutsch, M., Montague, E., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121101 · Cited by 2,194
Self-citationDose-Response Effect of Adjuvant Chemotherapy in Breast Cancer
Bonadonna, G., & Valagussa, P. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040103 · Cited by 774
Robins, J., Breslow, N., & Greenland, S. (1986) · Biometrics · doi:10.2307/2531052 · Cited by 476
CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCER
(1985) · The Lancet · doi:10.1016/s0140-6736(85)92206-8 · Cited by 309
Treatment of Primary Breast Cancer with Chemotherapy and Tamoxifen
Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E. R., Plotkin, D., Bowman, D., Sachs, S., Wolter, J., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050101 · Cited by 287
Self-citationFisher, B., Redmond, C., Brown, A., Wickerham, D. L., Wolmark, N., Allegra, J., Escher, G., Lippman, M., Savlov, E., & Wittliff, J. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.4.227 · Cited by 260
Self-citation
Cited by
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M. E., Koo, J., Madarnas, Y., Hartwick, W., Hoffman, B., & Hood, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.42 · Cited by 981
Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., Goodman, M. T., Giuliano, A. E., Karanja, N., McAndrew, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj494 · Cited by 825
Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., Fleming, G. F., Formenti, S., Hudis, C., Kirshner, J. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1539 · Cited by 816
Venous Thromboembolism and Cancer: Risks and Outcomes
Lee, A. Y. Y., & Levine, M. N. (2003) · Circulation · doi:10.1161/01.cir.0000078466.72504.ac · Cited by 721
Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., Wickerham, D. L., Yothers, G., Soran, A., & Wolmark, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.517 · Cited by 714
Self-citationMeeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Wood, W. C., Senn, H.-J., Glick, J. H., & Gelber, R. D. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1441 · Cited by 689
Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Self-citationDose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 577
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Fisher, B., Dignam, J., Emir, B., Bryant, J., DeCillis, A., Wolmark, N., Wickerham, D. L., Dimitrov, N. V., Abramson, N., Atkins, J. N., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1673 · Cited by 521
Self-citationWapnir, I. L., Anderson, S. J., Mamounas, E. P., Geyer, C. E., Jeong, J.-H., Tan-Chiu, E., Fisher, B., & Wolmark, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3273 · Cited by 466
Self-citationPartridge, A. H., Burstein, H. J., & Winer, E. P. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003451 · Cited by 426
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., & Senn, H.-J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1601 · Cited by 380
Markman, M., & Mekhail, T. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.6.755 · Cited by 375
Fisher, B., Jeong, J.-H., Bryant, J., Anderson, S., Dignam, J., Fisher, E. R., & Wolmark, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16981-x · Cited by 359
Self-citationHigh HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Pick, E., Kluger, Y., Giltnane, J. M., Moeder, C., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4511 · Cited by 356
Wildiers, H., Kunkler, I., Biganzoli, L., Fracheboud, J., Vlastos, G., Bernard-Marty, C., Hurria, A., Extermann, M., Girre, V., Brain, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70378-9 · Cited by 338
A current view of tamoxifen for the treatment and prevention of breast cancer
Jordan, V. C. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13840.x · Cited by 299
Crivellari, D., Bonetti, M., Castiglione-Gertsch, M., Gelber, R. D., Rudenstam, C.-M., Thürlimann, B., Price, K. N., Coates, A. S., Hürny, C., Bernhard, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1412 · Cited by 291
Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.931 · Cited by 272
Self-citationPritchard, K. I., Paterson, A. H., Paul, N. A., Zee, B., Fine, S., & Pater, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2731 · Cited by 269
Albain, K. S., Barlow, W. E., Ravdin, P. M., Farrar, W. B., Burton, G. V., Ketchel, S. J., Cobau, C. D., Levine, E. G., Ingle, J. N., Pritchard, K. I., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61523-3 · Cited by 258
Prescribers’ attitudes toward elderly breast cancer patients. Discrimination or empathy?
Protière, C., Viens, P., Rousseau, F., & Moatti, J. P. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.09.007 · Cited by 59
Metadata
- Authors
- Fisher, B., Redmond, C., Legault-Poisson, S., Dimitrov, N. V., Brown, A. M., Wickerham, D. L., Wolmark, N., Margolese, R. G., Bowman, D., & Glass, A. G.
- Venue
- Journal of Clinical Oncology
- Published
- 1990-06
- Volume
- 8
- Issue
- 6
- Pages
- 1005-1018
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128069055
- Cited by
- 291
- References
- 14
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.